- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03273062
A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury
A Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Cognition and Neuropsychiatric Symptoms in Patients With a History of Acquired Brain Injuries
This is a follow-up study for an ongoing open label trial conducted by the Sheppard Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT) inhibitor Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in patients with brain injuries (BI).
In this study, investigators will conduct a double-blind, placebo-controlled clinical trial utilizing a crossover design to study the effects of two weeks of Tolcapone 200mg administered three times a day (total of 600mg/day) on cognitive performance. Physical, emotional, cognitive and social functioning will also be evaluated through participant and proxy report. The investigators are planning to randomize a total of 12 patients with a history of acquired brain injury (BI).
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
The proposed study is a follow-up study for an ongoing open label trial conducted by the Sheppard Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT) inhibitor Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in patients with brain injuries (BI).
The outcome measures utilized in this study were chosen based on the available data from the currently ongoing open-label clinical trial. The proposed study will utilize the same study medication at the same dose and frequency. In addition, the length of administration of study medication (two weeks) is identical. In the proposed study, investigators will conduct a double-blind, placebo-controlled clinical trial utilizing a crossover design to study the effects of two weeks of Tolcapone 200mg administered three times a day (total of 600mg/day) on cognitive performance. Physical, emotional, cognitive and social functioning will be evaluated through participant and proxy report. The investigators are planning to randomize a total of 12 patients with BI.
The cross-over design requires two 2-week long study periods during which the participant receives either Tolcapone two 100mg capsules three times a day (total of 600mg/day) or placebo. Participants will be randomly assigned to two sequence groups either starting with Tolcapone treatment (T-P group) or placebo (P-T group). Investigators and participants will be blind to the study group assignment and hence blind to the treatment (Tolcapone vs. placebo) that subjects receive at a given time. The study periods are separated by a "washout period" that is at least two weeks and maximally 4 weeks long to reduce the potential for carryover effects. Patient reported outcomes will be obtained a total of four times, twice prior to the start of each respective study period (Pre-Study Period Visits I & II) as well as at the end of each study period (Outcome Measures Visits I & II). Cognitive outcome measures will be obtained twice throughout the study, at the end of each respective study period (Outcome Measures Visits I & II).
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Robert J Schloesser, MD
- Número de teléfono: 410-938-4610
- Correo electrónico: rschloesser@sheppardpratt.org
Copia de seguridad de contactos de estudio
- Nombre: Emily A Berich, BS
- Número de teléfono: 410-938-4610
- Correo electrónico: eberich@sheppardpratt.org
Ubicaciones de estudio
-
-
Maryland
-
Towson, Maryland, Estados Unidos, 21204
- Reclutamiento
- Sheppard Pratt Health System
-
Contacto:
- Robert J Schloesser, MD
- Número de teléfono: 410-938-4666
- Correo electrónico: rscloesser@sheppardpratt.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Capacity for written informed consent
- Ages 18-70 years, inclusive
- Diagnosis of a BI including mild, moderate, or severe TBI, or other acquired BI and post-BI development of neuropsychiatric complaints.
- Index event resulting in Traumatic or Acquired Brain Injury occurred >12 months prior to trial initiation
- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of BI
- Proficient in the English language
- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
- Stable neurological and psychiatric symptomatology for two months prior to trial initiation as determined by the referring Sheppard Pratt physician.
- Stable medication dose and regimen for two months prior to trial initiation (based on a review of medical chart)
Exclusion Criteria:
- History of, or active, liver disease or abnormal liver function tests-if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST: ALT has exceeded 2:1
- Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic <90mmHg or diastolic <60mmHg Hypertension: Systolic >140mmHg or diastolic >90 mmHg)
- Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
- Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
- Patient is currently taking Tolcapone or any of the following medications that can interact with Tolcapone resulting in an adverse event: another COMT inhibitor, benserazide, α-methyldopa, Dobutamine, Apomorphine, Isoproterenol, Clozapine, MAO inhibitor
- Known allergy or serious adverse reaction to Tolcapone
- Participated in any investigational drug trial within the past 30 days.
- Pregnant or planning to become pregnant during the study period
- Breastfeeding or planning to breastfeed during the study period.
- Presence of severe pre-morbid/pre-BI cognitive impairment or behavioral dysfunction, as per informant or medical documentation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Study Period 1
15 days of Tolcapone 200mg TID OR Placebo Comparator 15 days of Placebo pill TID |
Tolcapone 200 MG TID
Otros nombres:
Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
|
Comparador de placebos: Study Period 2
15 days of Placebo pill TID OR Active Comparator 15 days of Tolcapone 200mg TID |
Tolcapone 200 MG TID
Otros nombres:
Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
NIH Toolbox Fluid Cognitive Battery
Periodo de tiempo: Administered on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
This battery is a measure of cognitive performance derived from a battery of five cognitive assessments.
|
Administered on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
TBI Quality-of-Life Measurement System
Periodo de tiempo: Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
A patient reported outcome measure assessing physical, emotional, cognitive and social functioning.
Quality of Life Measure is a computer adaptive questionnaire.
|
Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Frontal Systems Behavior Scale
Periodo de tiempo: Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
A patient reported outcome measure, and proxy reported outcome measure, assessing neuropsychiatric symptoms associated with prefrontal cortical dysfunction
|
Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Robert J Schloesser, MD, Sheppard Pratt Health System
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Daño Cerebral Crónico
- Trauma craneoencefálico
- Trauma, Sistema Nervioso
- Lesiones Cerebrales
- Heridas y Lesiones
- Lesiones Cerebrales Traumáticas
- Lesión Cerebral Crónica
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antiparkinsonianos
- Agentes contra la discinesia
- Inhibidores de la catecol O-metiltransferasa
- Tolcapona
Otros números de identificación del estudio
- 1087860-3
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Lesiones Cerebrales
-
University of Dublin, Trinity CollegeDesconocidoAtletas de élite retirados de Brain Health
-
Assiut UniversityTerminadoMorfometría basada en Brain Voxel en ManiaEgipto
Ensayos clínicos sobre Tolcapone 200 MG
-
JW PharmaceuticalTerminadoDisfuncion erectilCorea, república de
-
Haudongchun Co., Ltd.DesconocidoVaginosis bacteriana | HUDC_VT | HaudongchunCorea, república de
-
Yuhan CorporationTerminado
-
Dr. Chris McGlory, PhDIovate Health Sciences International IncReclutamiento
-
Mylan Pharmaceuticals IncTerminadoSaludableEstados Unidos
-
Novartis PharmaceuticalsReclutamientoCarcinoma de pulmón de células no pequeñasIndia
-
Chong Kun Dang PharmaceuticalTerminadoVoluntarios SaludablesCorea, república de
-
Novelfarma Ilaç San. ve Tic. Ltd. Sti.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiTerminado
-
NP TherapeuticsTerminadoCOVID-19 | Voluntarios SaludablesFederación Rusa
-
Shanghai Jiatan Pharmatech Co., LtdTerminado